Empagliflozin in Heart Failure with a Preserved Ejection Fraction

D. Anker, Stefan; Butler, Javed; Filippatos, Gerasimos; Pedro Ferreira, João; Alcides Bocchi, Edimar; Böhm, Michael; Brunner‐La Rocca, Hans‐Peter; Choi, Dong‐Ju; Chopra, Vijay; Chuquiure‐Valenzuela, Eduardo; Giannetti, Nadia; Esteban Gómez‐Mesa, Juan; Janssens, Stefan; L. Januzzi, James; Ramón González‐Juanatey, José; Merkely, Béla; J. Nicholls, Stephen; V. Perrone, Sergio; L. Piña, Ileana; Ponikowski, Piotr; Senni, Michele; Sim, David; Špinar, Jindřich; Squire, Iain; Taddei, Stefano; Tsutsui, Hiroyuki; Verma, Subodh; Vinereanu, Dragoş; Zhang, Jian; E. Carson, Peter; S.P. Lam, Carolyn; Marx, Nikolaus; Zeller, Cordula; Sattar, Naveed; Jamal, Waheed; Schnaidt, Sven; Schnee, Janet; Brueckmann, Martina; Pocock, Stuart; Zannad, Faı̈ez; Packer, Milton

doi:10.1056/nejmoa2107038

Public

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Published in New England Journal of Medicine • Aug 27, 2021

Authors:

Stefan D. Anker

Javed Butler

Gerasimos Filippatos

Abstract

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. METHODS: In this double-blind t...

Subject

Empagliflozin

Ejection fraction

Heart failure

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!